BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 therapy in terms of drug-related adverse events. Secondary objectives are the collection of overall safety and antitumour efficacy data and the determination of the pharmacokinetic profile of BI 6727.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumours, who have failed conventional treatment, or for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment
Age 18 years or older
Written informed consent consistent with ICH-GCP and local legislation
Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score ¿ 2
Recovery from CTCAE Grade 2 - 4 therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies (except alopecia)
The 18 additional patients recruited at the MTD must also meet the following criterion:
Measurable tumour deposits (RECIST) by one or more techniques (CT, MRI)
Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol
Pregnancy or breastfeeding
Active infectious disease or known chronic Hepatitis B/Hepatitis C infection
Clinical evidence of active brain or leptomeningeal disease during the past 12 months
Second malignancy currently requiring active therapy
Absolute neutrophil count less than 1500 / mm3
Platelet count less than 100 000 / mm3
Bilirubin greater than 1.5 mg / dl (> 26 ¿mol / L, SI unit equivalent)
Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
Serum creatinine greater than 1.5 mg / dl (> 132 ¿mol / L, SI unit equivalent)
Known history of relevant QT-prolongation, e.g. long QT-syndrome
Women and men who are sexually active and unwilling to use a medically acceptable method of contraception
Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)
Chemo-, radio or immunotherapy within the past four weeks before start of therapy or concomitantly with this trial. This restriction does not apply to steroids and bisphosphonates.